About: Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
Creator	Bishop, Michael Dholaria, Bhagirathbhai Maziarz, Richard Bachanova, Veronika Dahi, Parastoo Grupp, Stephan Hayes-Lattin, Brandon Janakiram, Murali Nastoupil, Loretta Oluwole, Olalekan Perales, Miguel-Angel Porter, David Riedell, Peter Mcguirk, Joseph
Source	Elsevier; Medline; PMC; WHO
abstract	The SARS-CoV-2 coronavirus (COVID-19) pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources. Based on the collective experience of the CAR T-cell Consortium investigators, we review and address several questions and concerns regarding cellular therapy administration in the setting of COVID-19 and make general recommendations to address these issues. Specifically, we address (1) necessary resources for safe administration of cell therapies; (2) determinants of cell therapy utilization; (3) selection among patients with B cell non-Hodgkin lymphomas and B cell acute lymphoblastic leukemia; (4) supportive measures during cell therapy administration; (5) use and prioritization of tocilizumab; and (6) collaborative care with referring physicians. These recommendations were carefully formulated with the understanding that resource allocation is of the utmost importance, and that the decision to proceed with CAR T cell therapy will require extensive discussion of potential risks and benefits. Although these recommendations are fluid, at this time it is our opinion that the COVID-19 pandemic should not serve as reason to defer CAR T cell therapy for patients truly in need of a potentially curative therapy.
has issue date	2020-04-14(xsd:dateTime)
bibo:doi	10.1016/j.bbmt.2020.04.008
bibo:pmid	32298807
has license	no-cc
sha1sum (hex)	61e0606b285a2882cb7d346d6e2f10147cdc8eca
schema:url	https://doi.org/10.1016/j.bbmt.2020.04.008
resource representing a document's title	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
has PubMed Central identifier	PMC7194685
has PubMed identifier	32298807
schema:publication	Biol Blood Marrow Transplant
resource representing a document's body	covid:61e0606b285a2882cb7d346d6e2f10147cdc8eca#body_text
is schema:about of	named entity 'therapy' named entity 'B cell' named entity 'therapy' named entity 'B cell' named entity 'health care' named entity 'Pandemic' named entity 'cell therapy' named entity 'referring' named entity 'pandemic' named entity 'impacted' named entity 'T cell' named entity 'CAR' named entity 'care' named entity 'chimeric antigen receptor' named entity 'resource allocation' named entity 'SARS-CoV-2' named entity 'cellular therapy' named entity 'CRS' named entity 'infection control' named entity 'cellular therapy' named entity 'lymphoma' named entity 'COVID' named entity 'symptom' named entity 'multiple myeloma' named entity 'disease burden' named entity 'CD19' named entity 'FDA' named entity 'CRS' named entity 'COVID' named entity 'tocilizumab' named entity 'SARS-CoV-2' named entity 'COVID-19 testing' named entity 'infectious disease' named entity 'CAR T cell' named entity 'Nektar Therapeutics' named entity 'refractory' named entity 'immunocompromised patients' named entity 'comorbidities' named entity 'CAR T cell' named entity 'ECOG' named entity 'COVID' named entity 'follow-up' named entity 'AbbVie' named entity 'cellular therapy' named entity 'etiologies' named entity 'comorbidities' named entity 'Novartis' named entity 'tocilizumab' named entity 'DLBCL' named entity 'CAR T-cell' named entity 'refractory' named entity 'hypogammaglobulinemia' named entity 'Kymriah' named entity 'functional status' named entity 'social distancing' named entity 'NHL' named entity 'Performance status' named entity 'turnaround time' named entity 'disease burden' named entity 'assay' named entity 'BMS' named entity 'antiviral' named entity 'serum' named entity 'COVID-19 pandemic' named entity 'antibody' named entity 'infection' named entity 'CRS' named entity 'performance status'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software